Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article covers discussions from the Society of Urologic Oncology Annual Meeting outlining that new therapies, such as Provenge, Prostvac, and denosumab, are making the treatment of advanced prostate cancer more complex but may offer extended survival benefits.

This discussion proposes a model to incorporate patients with hormone-resistant prostate cancer into the existing framework by redefining hormone resistance and exploring new therapeutic approaches.

New treatments for prostate cancer are less toxic and show promise, but more research is needed to enhance their effectiveness and reduce side effects.

The Androgen Receptor could be a target for treating diseases like cancer, but more research is needed to confirm the effectiveness of potential treatments.

This study developed a DPC cell line by introducing mutant CDK4, Cyclin D1, and TERT, making it a promising tool to study downstream signaling pathways activated by testosterone in androgenetic alopecia.

This article outlines the author's personal strategies for managing dermatological toxicities, such as acneiform rash and dry skin, associated with EGFR inhibitor therapy; it does not present new research findings.

This study reported that while general patient characteristics and adverse event incidence for eribulin were comparable between a healthcare claims database and post-marketing surveillance, significant differences in some side effects such as neutropenia were observed.

This review discusses the biochemical properties and clinical significance of 5 alpha-reductase isozymes and reports no new clinical results.

This study found that using an oral contraceptive with bicalutamide significantly reduced hirsutism in women with PCOS compared to an oral contraceptive alone, although it increased total cholesterol and LDL levels.

This review discusses AR-modulating agents developed between 2012 and 2018, highlighting challenges with ligand-binding domain antagonists and proposing nonconventional approaches targeting other domains as promising strategies.

This study found that African American men with prostate cancer have higher rates of somatic and germline androgen receptor mutations than Caucasian American men, which may contribute to ethnic differences in disease progression and outcomes.

This review discusses potential treatments for androgen excess in polycystic ovary syndrome and reports no new findings, emphasizing the importance of individualized antiandrogenic management to minimize side effects.

This study found that dutasteride more effectively inhibited androgen receptor signaling and reduced cell growth compared to finasteride in prostate cancer cell models, with varying sensitivities across different cell lines.

This review discusses various targets for treating prostate cancer and benign prostatic hyperplasia and reports on recent studies of new compounds and 5α-reductase inhibitors, but provides no new experimental results.

This case report suggests that spironolactone may induce prostate cancer proliferation in patients on abiraterone acetate, advising against its use for managing treatment-associated side effects in these individuals.

This study identified novel 4-Amino-2H-benzo[h]chromen-2-one analogs as potent androgen receptor antagonists that show strong antiproliferative activity against prostate cancer cells, suggesting them as potential lead compounds for therapy development.

This review discusses the 2011 publications on the side effects of sex hormones and related compounds, without reporting new clinical results.

This study found that a novel thiohydantoin derivative, 3a, effectively inhibited androgen receptor activity in LNCaP cells and showed promising in vivo results by reducing testosterone-induced prostate changes, outperforming finasteride in mitigating prostate index and histopathological alterations.

This review examines the patent literature on AKR1C3 inhibitors and suggests that although numerous potent inhibitors exist, further preclinical optimization is necessary before assessing their therapeutic potential in human diseases.

This review discusses androgen receptor targeting as a potential treatment strategy for triple-negative breast cancer and reports no new experimental outcomes.

This study found that the novel drug VDC-1101 showed a 45% objective response rate in treating canine cutaneous T-cell lymphoma, offering a potential treatment option for this challenging disease.

This study found that expert consensus endorsed myo-inositol, alone or combined with folic acid and vitamin D₃, as an effective, well-tolerated option for managing acne and hirsutism in PCOS.

This review discusses how increased gene copy number for telomerase components may contribute to telomerase up-regulation in cancer cells, although the exact mechanisms are not fully understood.

This article discusses the challenges of attributing skin manifestations to COVID-19, emphasizing the need for more studies to differentiate virus-specific lesions from nonspecific ones, and reports no new clinical results.

This study identified peripheral myeloid cells as the earliest dysregulated immune cells in PINK1 KO mice with Parkinson’s-like symptoms following intestinal infections, suggesting that PINK1 regulates gut immune functions linked to early Parkinson’s disease mechanisms.

This clinical case study describes an aggressive squamous cell carcinoma developing within a giant epidermal cyst on the abdomen.

This study found that DVd therapy is at least as effective as VAD/VAd for treating multiple myeloma and causes fewer side effects and reduced hospital visits.

This study observed that MIRV improved gastrointestinal symptoms and other quality of life measures in patients with platinum-resistant ovarian cancer compared to chemotherapy.

A new, quick method accurately detects minoxidil in drugs and cosmetics.

This article reviews approved treatments for androgenetic alopecia and reports no new research findings, highlighting the need for further studies.